Ruffer LLP Has $3.50 Million Stock Holdings in Royalty Pharma PLC $RPRX

Ruffer LLP cut its position in Royalty Pharma PLC (NASDAQ:RPRX) by 30.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 90,432 shares of the biopharmaceutical company’s stock after selling 39,752 shares during the quarter. Ruffer LLP’s holdings in Royalty Pharma were worth $3,500,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in RPRX. Smartleaf Asset Management LLC grew its position in Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 790 shares during the period. Private Trust Co. NA increased its stake in Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 288 shares in the last quarter. Financial Consulate Inc. bought a new stake in Royalty Pharma during the 3rd quarter valued at $35,000. Larson Financial Group LLC increased its stake in Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 306 shares in the last quarter. Finally, Richardson Financial Services Inc. bought a new stake in Royalty Pharma during the 3rd quarter valued at $54,000. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Marshall Urist sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $41.09, for a total value of $821,800.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Terrance P. Coyne sold 114,954 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $42.84, for a total value of $4,924,629.36. Following the completion of the transaction, the chief financial officer owned 23,972 shares in the company, valued at $1,026,960.48. The trade was a 82.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 387,914 shares of company stock worth $16,879,974 in the last 90 days. Company insiders own 18.84% of the company’s stock.

Analyst Upgrades and Downgrades

RPRX has been the subject of a number of recent research reports. UBS Group boosted their price target on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday. The Goldman Sachs Group reiterated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, February 12th. Citigroup lifted their price target on Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Weiss Ratings upgraded Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, February 12th. Finally, TD Cowen reiterated a “buy” rating on shares of Royalty Pharma in a research note on Friday, February 27th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Royalty Pharma has an average rating of “Buy” and an average target price of $50.33.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $49.48 on Wednesday. Royalty Pharma PLC has a twelve month low of $31.58 and a twelve month high of $50.08. The stock’s 50 day moving average price is $46.66 and its 200-day moving average price is $41.78. The company has a market capitalization of $28.54 billion, a PE ratio of 36.65, a PEG ratio of 3.15 and a beta of 0.39. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.88.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%.The firm had revenue of $621.99 million for the quarter, compared to the consensus estimate of $839.97 million. On average, equities analysts anticipate that Royalty Pharma PLC will post 5.08 EPS for the current year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Friday, May 15th. Royalty Pharma’s payout ratio is presently 69.63%.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.